JP2005525317A - Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療 - Google Patents

Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療 Download PDF

Info

Publication number
JP2005525317A
JP2005525317A JP2003561517A JP2003561517A JP2005525317A JP 2005525317 A JP2005525317 A JP 2005525317A JP 2003561517 A JP2003561517 A JP 2003561517A JP 2003561517 A JP2003561517 A JP 2003561517A JP 2005525317 A JP2005525317 A JP 2005525317A
Authority
JP
Japan
Prior art keywords
dose
administered
total weekly
week
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003561517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525317A5 (enExample
Inventor
マウリス ジェイ． ウォリン，
サンドラ ミラン，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2005525317A publication Critical patent/JP2005525317A/ja
Publication of JP2005525317A5 publication Critical patent/JP2005525317A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2003561517A 2002-01-18 2003-01-18 Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療 Withdrawn JP2005525317A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34915802P 2002-01-18 2002-01-18
PCT/US2003/001394 WO2003061571A2 (en) 2002-01-18 2003-01-18 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein

Publications (2)

Publication Number Publication Date
JP2005525317A true JP2005525317A (ja) 2005-08-25
JP2005525317A5 JP2005525317A5 (enExample) 2006-03-02

Family

ID=27613252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561517A Withdrawn JP2005525317A (ja) 2002-01-18 2003-01-18 Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療

Country Status (6)

Country Link
US (1) US20030235556A1 (enExample)
EP (1) EP1569689A4 (enExample)
JP (1) JP2005525317A (enExample)
AU (1) AU2003210549A1 (enExample)
CA (1) CA2472186A1 (enExample)
WO (1) WO2003061571A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956266B2 (en) 2008-07-17 2018-05-01 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956266B2 (en) 2008-07-17 2018-05-01 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
US11235031B2 (en) 2008-07-17 2022-02-01 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Also Published As

Publication number Publication date
CA2472186A1 (en) 2003-07-31
US20030235556A1 (en) 2003-12-25
WO2003061571A3 (en) 2005-07-07
EP1569689A2 (en) 2005-09-07
EP1569689A4 (en) 2009-08-05
WO2003061571A2 (en) 2003-07-31
AU2003210549A8 (en) 2005-11-17
AU2003210549A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
US7306801B2 (en) Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
JP2003528155A (ja) Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法
KR20190104554A (ko) 피하 her 2 항체 제형
JP2003520195A (ja) 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
JP2022521792A (ja) 癌を治療するための免疫療法的併用
CN108883166B (zh) 以成为疾病主要原因的生物体内蛋白质为靶标的结合疫苗
JP7611136B2 (ja) 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬
TWI728400B (zh) Cd226促效劑抗體
JP2005538034A (ja) 非ホジキンリンパ腫の治療方法
US20210246219A1 (en) Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
KR20080110987A (ko) 항-ｅｇｆｒ 및 항-ｈｅｒ２ 항체를 이용하는 조합 요법
US12281147B2 (en) Interleukin 21 variants
KR20220097952A (ko) 암 치료를 위한 her2/4-1bb 이중특이적 융합 단백질
KR101972533B1 (ko) 전립선암 치료용 항-알파-ｖ 인테그린 항체
KR20220140534A (ko) 암 치료를 위한 egfr 억제제와 ror1 억제제의 조합
US20030235556A1 (en) Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
WO2024251200A1 (en) Engineered il-7 variants and methods of use thereof
WO2024192373A1 (en) Interferon alpha-2 variants
KR20230167025A (ko) 4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도
US11773160B1 (en) Immune-stimulating IL-2 fusion proteins
US20070274948A1 (en) Methods of Therapy for Chronic Lymphocytic Leukemia
US20240156974A1 (en) Compositions and methods for modulation of antibody activity
EP1935431A2 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
AU2023356118A1 (en) Use of c/ebp-beta antagonist and immunomodulator

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060111

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080904